169 related articles for article (PubMed ID: 27191542)
1. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients.
Rehfeld JF; Federspiel B; Agersnap M; Knigge U; Bardram L
Scand J Gastroenterol; 2016 Oct; 51(10):1172-8. PubMed ID: 27191542
[TBL] [Abstract][Full Text] [Related]
2. The cckOMA syndrome and its relation to the Zollinger-Ellison syndrome: a diagnostic challenge.
Rehfeld JF
Scand J Gastroenterol; 2024 May; 59(5):533-542. PubMed ID: 38299632
[TBL] [Abstract][Full Text] [Related]
3. Hormonal tumor mapping for liver metastases of gastroenteropancreatic neuroendocrine neoplasms: a novel therapeutic strategy.
Maekawa A; Kudo A; Kishino M; Murase Y; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Ogawa K; Ono H; Tanaka S; Kinowaki Y; Tanabe M
J Cancer Res Clin Oncol; 2022 Mar; 148(3):697-706. PubMed ID: 33904982
[TBL] [Abstract][Full Text] [Related]
4. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
5. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors.
van Adrichem RC; Kamp K; Vandamme T; Peeters M; Feelders RA; de Herder WW
Ann Oncol; 2016 Apr; 27(4):746-7. PubMed ID: 26712902
[No Abstract] [Full Text] [Related]
6. The analysis of immunophenotype of gastrin-producing tumors of the pancreas and gastrointestinal tract.
Gurevich L; Kazantseva I; Isakov VA; Korsakova N; Egorov A; Kubishkin V; Bulgakov G
Cancer; 2003 Nov; 98(9):1967-76. PubMed ID: 14584081
[TBL] [Abstract][Full Text] [Related]
7. Syndromic versus non-syndromic sporadic gastrin-producing neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior.
Rosentraeger MJ; Garbrecht N; Anlauf M; Raffel A; Knoefel WT; Wiedenmann B; Klöppel G
Virchows Arch; 2016 Mar; 468(3):277-87. PubMed ID: 26649731
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute.
Shin Y; Ha SY; Hyeon J; Lee B; Lee J; Jang KT; Kim KM; Park YS; Park CK
Cancer Res Treat; 2015 Oct; 47(4):738-46. PubMed ID: 25687852
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger.
Rehfeld JF
Front Endocrinol (Lausanne); 2017; 8():47. PubMed ID: 28450850
[TBL] [Abstract][Full Text] [Related]
10. Circadian variations in plasma concentrations of cholecystokinin and gastrin in man.
Rehfeld JF; Sennels HP; Jørgensen HL; Fahrenkrug J
Scand J Clin Lab Invest; 2020 Nov; 80(7):546-551. PubMed ID: 32820681
[TBL] [Abstract][Full Text] [Related]
11. The role of gastrointestinal peptides on pancreatic secretion in response to different stimulants in conscious rats.
Ami M; Doi R; Inoue K; Chowdhury P; Rayford PL
Int J Pancreatol; 1993 Dec; 14(3):245-52. PubMed ID: 8113626
[TBL] [Abstract][Full Text] [Related]
12. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours.
Stridsberg M; Eriksson B; Lundqvist G; Skogseid B; Wilander E; Oberg K
Regul Pept; 1995 Jan; 55(2):119-31. PubMed ID: 7754100
[TBL] [Abstract][Full Text] [Related]
13. Hypergastrinemia as a cause of chromogranin a increase in blood in patients suspected to have neuroendocrine tumor.
Kleveland O; Syversen U; Slørdahl K; Waldum HL
Digestion; 2001; 64(2):71-4. PubMed ID: 11684818
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas.
Pavel ME; Hassler G; Baum U; Hahn EG; Lohmann T; Schuppan D
Clin Endocrinol (Oxf); 2005 Apr; 62(4):434-43. PubMed ID: 15807874
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival in MEN1 patients with gastrinomas: Results from the DutchMEN study group (DMSG).
van Beek DJ; Nell S; Pieterman CRC; de Herder WW; van de Ven AC; Dekkers OM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Borel Rinkes IHM; Vriens MR; Valk GD
J Surg Oncol; 2019 Nov; 120(6):966-975. PubMed ID: 31401809
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
17. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
18. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous expression of cholecystokinin and gastrin receptor in stomach and pancreatic cancer: An immunohistochemical study.
Rai R; Kim JJ; Tewari M; Shukla HS
J Cancer Res Ther; 2016; 12(1):411-6. PubMed ID: 27072272
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
